Evidence map›Paper›PMID 37749438›Full record

ArticleMolecular imaging and biology2023

Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [

Mads Lawaetz, Tina Binderup, Anders Christensen, Karina Juhl, Giedrius Lelkaitis, Eva Lykke, Line Knudsen, Christian von Buchwald, Andreas Kjaer

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mads LawaetzDepartment of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. madslawaetz@gmail.com.
Tina BinderupDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Anders ChristensenDepartment of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Karina JuhlDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Giedrius LelkaitisDepartment of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Eva LykkeDepartment of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Line KnudsenDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Christian von BuchwaldDepartment of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Andreas KjaerDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Rigshospitalet · DKUniversity of Copenhagen · DKCopenhagen University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose[ PROCEDURES: PDX flank tumor models were established by engrafting tumor tissue from three patients with locally advanced OSCC into immunodeficient mice. [

resultsThree PDX models were established, and all of them showed histological stability and unchanged heterogenicity, uPAR expression, and Ki67 expression through passages. A significant correlation between uPAR expression and tumor growth was found. All tumors of all models (n=29) showed tumor uptake of [

conclusionsOSCC PDX models in early passages histologically mimic donor tumors and could serve as a valuable platform for the development of uPAR-targeted imaging and therapeutic modalities. Furthermore, [64Cu]Cu-uPAR-PET/CT showed target- and tumor-specific uptake in OSCC PDX models demonstrating the diagnostic potential of this modality for OSCC patients.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsAnimalsCopper RadioisotopesHeterocyclic Compounds, 1-RingHeterograftsHumansMicePositron Emission Tomography Computed TomographyReceptors, Urokinase Plasminogen ActivatorSquamous Cell Carcinoma of Head and Neck1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidCopper-64Copper RadioisotopesHeterocyclic Compounds, 1-RingReceptors, Urokinase Plasminogen Activator64Cu-DOTA-AE105Oral squamous cell carcinomaPatient-derived xenograft modelsPET/CTUrokinase-type plasminogen activator receptor

Identifiers

PMID37749438
PMCPMC10728257
OpenAlexW4387012177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.